After two years, TAVR was still linked to a reduction in the study’s primary endpoint, but it was also associated with a greater risk of valve thrombosis.
After two years, TAVR was still linked to a reduction in the study’s primary endpoint, but it was also associated with a greater risk of valve thrombosis.